Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are a type of multipotent stem cell being investigated for the treatment of diabetic erectile dysfunction. Developed and studied by Ankara City Hospital Bilkent, these cells are administered via a single intracavernosal injection into the corpus cavernosum. The therapeutic mechanism involves the secretion of paracrine factors that promote tissue regeneration, stimulate angiogenesis, provide neuroprotection, and exert anti-fibrotic effects within the penile tissue. This regenerative approach is specifically targeted at patients with a history of diabetes mellitus who have demonstrated an insufficient response to standard medical therapies, such as phosphodiesterase type-5 (PDE-5) inhibitors, aiming to restore penile hemodynamics and erectile function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (55a4df).